GLOBECHEKTM PRESENTS PILOT STUDY AT INTERNATIONAL RESEARCH SUMMIT (ARVO), READIES FOR OFFICIAL U.S. LAUNCH OF ITS UNRIVALED TELEOPHTHALMOLOGY GLOBE (ESG 1200)Posted May 09, 2019
Vero Beach, FL, May 7, 2019– GlobeChek™ Enterprises, LLC announced today that their tele-ophthalmology pilot study conducted at New York-Presbyterian/Columbia University Medical Center was highly successful at identifying asymptomatic people with vision threatening conditions. The study was directed by Dr. Lama Al-Aswad, Associate Professor of Ophthalmology at Columbia University Medical Center and Director of the glaucoma screening program at Columbia University. “Our study utilized a teleophthalmology GlobeChek™ kiosk - the first in the United States - at a location with high volume and accessibility in northern Manhattan (NY) and explored its benefit and feasibility in community-based screening program.” Over 300 participants were screened and the results were presented at this month’s ARVO National Meeting in Vancouver. Dr. Al-Aswad concluded, “Teleophthalmology using a GlobeChek kiosk was feasible and effective in identifying the four most common causes of blindness. Our study also demonstrates the potential of increasing the access of care and preventing blindness utilizing a teleophthalmology kiosk.”
GlobeChek™ is excited to introduce its first commercially available version of the Globe (ESG 1200) with a planned release date later this month. The newest Globe is considerably smaller and lighter allowing for easier placement and maneuverability, as well as being even more comprehensive. “We have added wavefront corneal topography, pachymetry, anterior segment OCT and cataract grading to our preexisting battery of tests,” reports Dr. William Mallon, CEO and co-founder of GlobeChek™. The Globe is already capable of checking visual acuity and performing autorefraction, intraocular pressure, OCT of the optic nerve and macula, as well as external and fundus photography. The first production run of the Globes has already been spoken for. “The Globes are headed to New York, Georgia, and Florida to name a few states. While we are not permitted to release specific details, expect to see them at public
Page | 2
hospitals, academic medical centers and airports in the near future,” states Dr. Adam Katz, President and co-founder of GlobeChek™.
“Our study also demonstrates the potential of increasing the access of care and preventing blindness utilizing a teleophthalmology kiosk.” - Lama A. Al-Aswad, MD, MPH GlobeChek™ seeks to bring visual health awareness and screening exams to the large percentage of the United States population that currently does not receive eye care. GlobeChek™ aims to provide convenient, affordable, non-invasive, comprehensive eye screening. Simply stated, the mission of GlobeChek™ is to enable health care providers to identify previously undiagnosed conditions, including asymptomatic glaucoma and diabetic retinopathy, and thereby allow earlier intervention.
About GlobeChek Enterprises, LLC. GlobeChek Enterprises, LLC was formed to develop and implement technology enabling a thorough screening eye exam. The company was founded by Adam M. Katz, MD and William J. Mallon, MD, two practicing Board-Certified Ophthalmologists with more than 40 years of combined experience. The goal of GlobeChek Enterprise, LLC is to provide convenient affordable access to medical eye screening exams in order to prevent asymptomatic people from losing vision.
# # #
If you would like more information about this topic, please contact William J. Mallon, MD at 1-877-GLOBECHEK or email at [email protected]
This release contains forward-looking statements that involve risks and uncertainties. We caution that these statements are not guarantees of future performance. They involve a number of risks and uncertainties that are difficult to predict. Actual results could differ materially from those expressed or implied in the forward-looking statements. Certain factors could cause actual results to differ materially from those in the forward-looking statements.